¥ 2383
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease;...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is underpriced on P/E, 'expensive' on EV/EBITDA, overvalu
Target Price
The average target price of 2160.T is 4347 and suggests 84% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
